Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chemotherapy alone A 37% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results